A key goal of clinical trials is to evaluate whether the potential new drug reaches its target safely, at sufficient exposure, and promotes the desired pharmacological effect. In addition to the parent drug, one should bear in mind the drug metabolites, which are formed when the parent drug goes through biotransformations in the body. Any potential toxicity of these metabolites, be they active or inactive, needs to be evaluated.
At Symeres, and our Admescope affiliate, we're able to identify metabolites (MetID), synthesize them, and characterize metabolite profiles through in vitro studies. To make the analysis complete, we can carry out follow-up studies using samples from in vivo studies in preclinical tox-species and humans. In some very recent blog posts, we told you all about how that can work for you. In addition, there is an on-demand webinar available on our website.